VYNE Therapeutics to Participate in Cantor Fitzgerald’s Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference Dec 2, 2022 08:00AM
Cantor Fitzgerald Reiterates VYNE Therapeutics (VYNE) at Overweight with $10 Price Target, Expects "Upwards Earnings Estimate Revisions and Multiple Expansion" May 13, 2022 06:27AM
Cantor Fitzgerald Reiterates VYNE Therapeutics (VYNE) at Overweight with $10 PT, Sees Latest FMX114 Data Underscoring "Positive Investment Thesis" Apr 7, 2022 09:08AM
Cantor Fitzgerald Reiterates VYNE Therapeutics (VYNE) Overwight, $10 PT, Sees Company's Bromodomain and Extra-Terminal Domain Inhibitors Programs are Underappreciated Mar 17, 2022 10:55AM
Cantor Fitzgerald Reiterates VYNE Therapeutics (VYNE) at Overweight, Newest Data Supports Positive Thesis for Stock Mar 7, 2022 07:36AM


Jan 13, 2022 08:12AM VYNE Therapeutics (VYNE) MST Sale is Good news, Underscores Company's Ability to Execute - Cantor Fitzgerald
Dec 28, 2021 05:55AM VYNE Therapeutics (VYNE) and Ardelyx (ARDX) Top Cantor Fitzgerald's Most Shorted Biotech List
Nov 10, 2021 01:31PM Cantor Fitzgerald Reiterates Overweight Rating on VYNE Therapeutics (VYNE)
Sep 20, 2021 08:00AM VYNE Therapeutics to Present at the Cantor Fitzgerald Investment Conference
Oct 29, 2020 07:15AM Companies with NDRs 10/29
Oct 28, 2020 06:53AM Companies with NDRs 10/28
Sep 9, 2020 08:00AM VYNE Therapeutics (formerly Menlo Therapeutics) to Present at the Cantor Fitzgerald and H.C. Wainwright Investment Conferences in September